TW200508239A - Method for preparing polymorphism of irinotecan hydrochloride - Google Patents
Method for preparing polymorphism of irinotecan hydrochlorideInfo
- Publication number
- TW200508239A TW200508239A TW093104774A TW93104774A TW200508239A TW 200508239 A TW200508239 A TW 200508239A TW 093104774 A TW093104774 A TW 093104774A TW 93104774 A TW93104774 A TW 93104774A TW 200508239 A TW200508239 A TW 200508239A
- Authority
- TW
- Taiwan
- Prior art keywords
- degrees
- preparing
- irinotecan hydrochloride
- polymorphism
- irinotecan
- Prior art date
Links
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 title abstract 4
- 229960000779 irinotecan hydrochloride Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 abstract 3
- 239000013078 crystal Substances 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 2
- 239000012535 impurity Substances 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003046908 | 2003-02-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200508239A true TW200508239A (en) | 2005-03-01 |
| TWI326684B TWI326684B (cg-RX-API-DMAC7.html) | 2010-07-01 |
Family
ID=32923248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093104774A TW200508239A (en) | 2003-02-25 | 2004-02-25 | Method for preparing polymorphism of irinotecan hydrochloride |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7488825B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1598356A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4566128B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101095382B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN100418970C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004215560B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0407791A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2516643C (cg-RX-API-DMAC7.html) |
| IL (1) | IL170350A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ541990A (cg-RX-API-DMAC7.html) |
| TW (1) | TW200508239A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004076460A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060046993A1 (en) * | 2004-09-01 | 2006-03-02 | Pharmacia Italia S.P.A. | Crystalline polymorphic form of irinotecan hydrochloride |
| WO2006038526A1 (ja) * | 2004-10-01 | 2006-04-13 | Kabushiki Kaisha Yakult Honsha | イリノテカン酸付加塩 |
| US7435818B2 (en) | 2005-09-20 | 2008-10-14 | Scinopharm Taiwan, Ltd. | Crystal forms of irinotecan hydrochloride |
| CN101318964B (zh) * | 2007-06-07 | 2010-12-15 | 上海迪赛诺医药发展有限公司 | 盐酸伊立替康新晶型及其制备方法 |
| US7572803B2 (en) * | 2007-10-25 | 2009-08-11 | The Christus Stehlin Foundation For Cancer Research | Hydrated crystalline esters of camptothecin |
| IT1391757B1 (it) * | 2008-11-11 | 2012-01-27 | Antibioticos Spa | Irinotecan cloridrato cristallino e metodi per la sua preparazione |
| CN102311443B (zh) * | 2011-08-24 | 2014-07-16 | 上海北卡医药技术有限公司 | 盐酸伊立替康的新晶型及其制备方法 |
| CN102617584B (zh) * | 2012-03-14 | 2013-10-16 | 海南锦瑞制药股份有限公司 | 一种盐酸伊立替康化合物及其药物组合物 |
| US10919905B2 (en) * | 2019-05-16 | 2021-02-16 | Scinopharm Taiwan, Ltd. | Polymorphism for irinotecan free base |
| CN111100135A (zh) * | 2019-10-24 | 2020-05-05 | 连云港杰瑞药业有限公司 | 一种盐酸伊立替康的精制方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6247193A (ja) | 1985-08-26 | 1987-02-28 | 内橋エステック株式会社 | 電子部品のはんだ付方法 |
| JPH034077A (ja) | 1989-05-30 | 1991-01-10 | Nissho Corp | 逆止弁 |
| JPH07277981A (ja) | 1994-04-12 | 1995-10-24 | Yakult Honsha Co Ltd | 徐放性抗腫瘍製剤 |
| JPH1017472A (ja) | 1996-07-04 | 1998-01-20 | Yakult Honsha Co Ltd | 徐放性抗腫瘍製剤 |
| CN1276923C (zh) * | 2002-03-01 | 2006-09-27 | 法玛西雅意大利公司 | 盐酸伊立替康的结晶多晶型物 |
-
2004
- 2004-02-24 CN CNB2004800047816A patent/CN100418970C/zh not_active Expired - Fee Related
- 2004-02-24 AU AU2004215560A patent/AU2004215560B2/en not_active Ceased
- 2004-02-24 CA CA2516643A patent/CA2516643C/en not_active Expired - Fee Related
- 2004-02-24 EP EP04714012A patent/EP1598356A4/en not_active Withdrawn
- 2004-02-24 JP JP2005502882A patent/JP4566128B2/ja not_active Expired - Fee Related
- 2004-02-24 KR KR1020057014560A patent/KR101095382B1/ko not_active Expired - Fee Related
- 2004-02-24 US US10/546,687 patent/US7488825B2/en not_active Expired - Fee Related
- 2004-02-24 NZ NZ541990A patent/NZ541990A/en not_active IP Right Cessation
- 2004-02-24 BR BRPI0407791-1A patent/BRPI0407791A/pt not_active IP Right Cessation
- 2004-02-24 WO PCT/JP2004/002126 patent/WO2004076460A1/ja not_active Ceased
- 2004-02-25 TW TW093104774A patent/TW200508239A/zh not_active IP Right Cessation
-
2005
- 2005-08-18 IL IL170350A patent/IL170350A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004076460A1 (ja) | 2004-09-10 |
| BRPI0407791A (pt) | 2006-02-14 |
| US20060234904A1 (en) | 2006-10-19 |
| US7488825B2 (en) | 2009-02-10 |
| JPWO2004076460A1 (ja) | 2006-06-01 |
| CN100418970C (zh) | 2008-09-17 |
| IL170350A (en) | 2010-11-30 |
| KR20050100661A (ko) | 2005-10-19 |
| AU2004215560B2 (en) | 2009-09-24 |
| NZ541990A (en) | 2009-04-30 |
| CN1751048A (zh) | 2006-03-22 |
| AU2004215560A1 (en) | 2004-09-10 |
| JP4566128B2 (ja) | 2010-10-20 |
| KR101095382B1 (ko) | 2011-12-16 |
| CA2516643C (en) | 2011-04-19 |
| EP1598356A1 (en) | 2005-11-23 |
| EP1598356A4 (en) | 2008-07-02 |
| TWI326684B (cg-RX-API-DMAC7.html) | 2010-07-01 |
| CA2516643A1 (en) | 2004-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200508239A (en) | Method for preparing polymorphism of irinotecan hydrochloride | |
| Charlier et al. | Magma chamber processes in the Tellnes ilmenite deposit (Rogaland Anorthosite Province, SW Norway) and the formation of Fe–Ti ores in massif-type anorthosites | |
| WO2009055216A3 (en) | Method of preparing a molecular sieve composition | |
| TW200740524A (en) | A molecular sieve composition | |
| SI1462442T1 (sl) | Kristali bikalutamida in postopek za njihovo pripravo | |
| WO2008107860A3 (en) | Large single crystal diamonds | |
| CA2632585A1 (en) | Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene and processes for preparing said compound | |
| ZA202305595B (en) | Crystal type ii of melanocortin receptor agonist compound and method for preparing same | |
| IN2012DN03176A (cg-RX-API-DMAC7.html) | ||
| GEP20094576B (en) | New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| WO2006095263A8 (en) | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds | |
| KR20180014015A (ko) | 엔잘루타미드 결정형의 제조 방법 | |
| EP1688410A4 (en) | CRYSTAL OF A PHENYL ALANINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF | |
| WO2009039362A3 (en) | Chiral synthesis of diazepinoquinolines | |
| TW200635939A (en) | Tantalum compound, method for producing the same, tantalum-containing thin film and method for forming the same | |
| WO2008102888A1 (ja) | 新規擬似糖脂質及びその用途 | |
| WO2007066158A3 (en) | HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF | |
| NO20054911L (no) | Fremgangsmate for fremstilling av et polymorft frosiglitazonmaleat | |
| UA90530C2 (uk) | СПОСІБ ОДЕРЖАННЯ 4β-АМІНО-4'-ДЕМЕТИЛ-4-ДЕЗОКСИПОДОФІЛОТОКСИНУ (ВАРІАНТИ) | |
| ATE479728T1 (de) | Neue kristallphase eines benzimidazolon-azo- pigments | |
| MX2009013336A (es) | Sintesis de 3-aminopirazoles sustituidos. | |
| KR100809159B1 (ko) | 로사탄의 개선된 제조방법 | |
| TW200609232A (en) | 1,4-dithienylbenzene derivatives | |
| WO2004099147A1 (es) | Compuesto intermedio útil para la preparación de pioglitazona | |
| TW200514770A (en) | Crystal of sulfonamide-containing indole compound and process for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |